Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Nov 03, 2015 11:18am
289 Views
Post# 24253658

RE:Panmure Gordon Update

RE:Panmure Gordon UpdateHey !  I think I made a similar IP under-valuation point yesterday !   I do like Gordon's numbers.  

It is often said that "the markets are truth"  ... I think this is one of those rare opportunities where the market's lack of confidence in mgmt,  that has been built on the foundation of repeated underperformance... has created a phenomenal opportunity...   where the market truly has this wrong.....underappreciating the value that has been created... and thats just the CDN equity institutions.    

I buy into the thesis that the IP build has been wholly under appreciated largely because of the Revenue disappointments and overpromising.... they are in the penalty box.... and given the relative small market cap,  the US / Internationals havent even begun to pay attention yet.  

If in fact mgmt can execute their baseline IND efficacy trials and PPPS plans....  and bring this whole value proposition to the Nasdaq,  something close to the true relative value should be unlocked in a rather violent manner.
Bullboard Posts